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Abstract 
Background: Chloroquine (CQ) is the first-line treatment for vivax malaria in Ethiopia, but there is evidence for its 
declining efficacy. Defining the extent and regional distribution of CQ resistance is critical to ensure optimal treatment 
guidelines. This study aimed to provide data on the therapeutic efficacy of CQ against Plasmodium vivax malaria in 
southern Ethiopia.
Methods: Patients with P. vivax mono-infection aged between 8 months and 65 years were enrolled in a clinical 
efficacy trial. The study was conducted at four sites in southern Ethiopia. Study participants were treated with a super-
vised course of CQ (25 mg/kg over three consecutive days), followed by weekly blood film examination and clinical 
assessment for 28 days. CQ blood concentrations were not assessed. The primary endpoint was the risk of failure at 
28 days by survival analysis.
Results: Between May 2010 and December 2013, 288 patients were enrolled in the study (n = 89 in Shele, n = 52 
in Guba, n = 57 in Batu and n = 90 in Shone). Baseline characteristics varied significantly between sites. In total 34 
(11.8 %) patients were censored during follow up (five with Plasmodium falciparum parasitaemia and 29 lost to follow 
up). Two (0.7 %) patients experienced early treatment failure and 23 (8 %) late treatment failure. The overall risk of 
recurrence by day 28 was 9.4 % (95 % CI 6.4–13.6 %) with site-specific estimates of 3.8 % (95 % CI 1.2–11.3) for Shele, 
21.9 % (95 % CI 12.2–36.1) for Guba, 5.9 % (95 % CI 1.9–17.3) for Batu and 9.2 % (95 % CI 4.5–17.6) for Shone.
Conclusion: There is evidence of reduced CQ efficacy across three of the four study sites, with the degree of resist-
ance severe enough in Guba to suggest that review of treatment policy may be warranted.
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Background
An estimated 2.85 billion people live at risk of Plasmo-
dium vivax infection worldwide [1, 2] with the number 
of annual infections ranging from 19 to 240 million cases 
[3]. The greatest burden of disease is found in South and 
Southeast Asia, although 10–20 % of all P. vivax malaria 
cases occur in Eastern and Southern Africa [1]. Over the 
last decade Plasmodium falciparum transmission has 
declined more rapidly than P. vivax in endemic regions 
and P. vivax is now emerging as the dominant species in 
many co-endemic areas [3, 4].
In Ethiopia, P. vivax accounts for approximately 40  % 
of all malaria infections [5]. Historically, there have been 
an estimated 10 million clinical malaria cases annually, 
although numbers have reduced substantially in the past 
decade. Since 2005, Ethiopia has scaled-up one of the 
largest and most ambitious malaria control programmes 
in Africa. The programme is designed to support the 
country‘s Health Sector Development Plan (HSDP), and 
the national child survival strategy, in order to reduce 
under-five mortality rates by two thirds by 2015 [6].
In most parts of the world chloroquine (CQ) remains 
the first-line treatment for P. vivax malaria. However, the 
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emergence of drug resistance has compromised its use [7, 
8] in several regions. Since 2004, artemether–lumefan-
trine (AL) has been used for uncomplicated falciparum 
malaria in Ethiopia, but CQ is still used for vivax malaria 
[5]. Several studies have documented reduced CQ sen-
sitivity against P. vivax in different regions of Ethiopia 
[9–11], although this appears sporadic, since other stud-
ies show sustained efficacy [12]. The evidence suggests an 
emerging pattern of declining CQ susceptibility in this 
region that will undermine control efforts for both fal-
ciparum and vivax malaria and emphasizes the need for 
ongoing surveillance of CQ efficacy.
The objective of the current clinical study was to pro-
vide an update on the therapeutic efficacy of CQ against 
P. vivax malaria in four locations in southern Ethiopia.
Methods
Study sites and participants
The study was conducted in Southern Ethiopia, at health 
centres located in Shele in Arba Minch Zuria district, 
Guba in Halaba district, Batu in Adami Tulu Jido Kom-
bolcha district and Shone in Eastern Badawacho district 
(Fig. 1) between May 2010 and December 2013. Patients 
attending outpatient clinics with signs and symptoms con-
sistent with malaria were screened for inclusion into the 
study. Inclusion criteria were as follows: age >6 months, P. 
vivax mono-infection with parasite densities above 250/
µl, an axillary temperature of ≥37.5 °C or history of fever 
within 48 h of presentation, residence in close proximity 
to the health centre (i.e. within 10 km radius) and willing-
ness to participate in the study and be followed up for at 
least 28 days. Written informed consent from the patient 
or in case of minors from a parent or guardian and assent 
from children aged 12–17 was obtained. Patients with 
manifestations of severe malaria as defined by the World 
Health Organization (WHO) criteria were excluded [13]. 
Patients were excluded if they had severe malnutrition, 
were pregnant or had clinically evidence of chronic dis-
ease, a history of allergies and/or intolerance to CQ, or 
taken any anti-malarial or antibiotic treatment within the 
previous 2 weeks.
Study design
The study design was based on the standard 28 day fol-
low up survey as defined by the WHO [14]. Patients with 
uncomplicated P. vivax infection were recruited and 
treated at the respective health centres. Patients were 
asked to return to the health centre on day 1 and 2 for 
directly observed treatment. Patients were then assessed 
at follow up visits on days 3, 7, 14, 21 and 28 or whenever 
they had signs and symptoms consistent with malaria. 
Patients failing to come to their scheduled appointments 
were visited at home.
Treatment
Quality-assured CQ (KT9363 and BN11747) from the 
Ethiopian Federal Ministry of Health was used as the 
study treatment. CQ was administered at 25  mg base/
kg body weight divided over 3  days (10  mg base/kg on 
day 0 and 1 and 5  mg base/kg on day 2). Study partici-
pants were observed for 30 min after administration and 
those vomiting their dose were treated again with the 
same dose of CQ and observed for an additional 30-min 
period. Patients failing to respond to CQ therapy were 
treated with quinine as a second line treatment [5]. 
Patients with a temperature  >38.0  °C were prescribed 
oral paracetamol. In line with current national treatment 
guidelines no primaquine was given [5].
Clinical procedures
A general physical examination was conducted at the 
enrollment visit. Baseline data on age, sex, weight and 
height were recorded. Adverse events were recorded at 
every visit. A finger prick blood sample was taken for 
microscopy at every follow up visit and any unscheduled 
visit. Haemoglobin was measured on the day of enrol-
ment and on day 28.
Laboratory procedures
Pregnancy test
All female study participants aged 12  years and older 
were tested for pregnancy. Urine human chorionic gon-
adotropin (HCG) dipstick test (ACON laboratories, INC. 
CA, USA) was used and pregnant women were excluded 
from the study.
Microscopy
Thick and thin blood smears were prepared in duplicate. 
Blood slides were stained with Giemsa, as described pre-
viously [14]. Blood films were read by two independent 
laboratory technicians from the health centre; in case of 
discordance a third reading was performed. Parasite den-
sities were recorded for all positive slides. The number of 
asexual parasites was counted per 200 white blood cells 
(WBC) and parasitaemia estimated assuming a WBC 
count of 8000/µl. Gametocytes were counted against 
100 fields. Before a slide was considered negative a total 
of 100 WBCs were counted [14]. A random set of 10 % 
of the slides were cross checked by another experienced 
laboratory technician for quality control at the Nazareth 
Malaria Control Centre.
Haemoglobin
One drop of blood was used to measure the haemoglo-
bin concentration on day 0, on the day of recurrent para-
sitaemia and on day 28 using Hemocue™ (Angelholm 
Sweden).
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Study endpoints
The primary endpoint of the study was risk of recurrence 
by day 28 [15]. Treatment failures were categorized as 
early (ETF), late parasitological failures (LPTF) and late 
clinical treatment failures (LCTF). ETFs were defined as 
one of the following: (1) the occurrence of danger signs or 
severe malaria on day 1, 2 or 3 in the presence of parasitae-
mia, (2) parasitaemia on day 2 higher than on day 0 irre-
spective of axillary temperature, (3) parasitaemia on day 
3 with axillary temperature ≥37.5  °C or (4) parasitaemia 
on day 3 ≥25 % of count on day 0. LCTFs were defined 
as the occurrence of danger signs or severe malaria in the 
presence of parasitaemia or the presence of parasitaemia 
on any day between day 4 and day 28 with axillary tem-
perature ≥37.5 °C (or history of fever) in patients who did 
not previously meet any of the criteria of early treatment 
failure. LPTFs were defined as the presence of parasitae-
mia on any day between day 7 and day 28 with axillary 
temperature <37.5  °C in patients who did not previously 
meet any of the criteria of early treatment failure or late 
clinical failure. Patients with no parasitaemia on day 28, 
irrespective of axillary temperature, and who did not 
previously meet any of the criteria of early treatment fail-
ure, late clinical failure or late parasitological failure were 
defined as adequate clinical and parasitological response 
(ACPR) [15]. Secondary endpoints were adjusted efficacy 
estimates at day 28 and parasite clearance.
Statistical analyses
Data were double entered into the WHO excel spread-
sheet. All statistical analyses were performed using 
STATA 13 (StatCorp, USA). The Mann–Whitney U test 
or Kruskal–Wallis method were used for nonparamet-
ric comparisons, and Student’s t test or one-way analysis 
of variance for parametric comparisons. For categorical 
variables percentages and corresponding 95  % confi-
dence intervals (95 % CI) were calculated using Wilson’s 
method. Proportions were examined using χ2 with Yates’ 
correction or by Fisher’s exact test. The cumulative risk 
of failure was assessed by survival analysis using the 
Kaplan–Meier method on a modified intention to treat 
basis. Anyone lost to follow up or presenting with P. falci-
parum infection was censored on their last day of follow 
up and regarded as not being treatment failures.
Fig. 1 Map of study sites
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Ethical consideration
The study protocols were reviewed and approved 
by the respective Ethical Boards of the Addis Ababa 
University College of Natural Sciences, Ethiopia 
(RERC/002/05/2013), the Armauer Hansen Research 
Institute, Addis Ababa, Ethiopia (AHRI-ALERT 
P011/10), the National Research Ethics Review Com-
mittee of Ethiopia (Ref.no. 3.10/580/06) and the Human 
Research Ethics Committee of the Northern Territory 
Department of Health and Menzies School of Health 
Research, Australia (HREC-13-1942). No participant was 
enrolled without prior written informed consent.
Results
Study profile and baseline characteristics
Overall 9737 patients were screened for inclusion into 
the study, 8017 (82.3 %) had no malaria, 868 (8.9 %) had a 
falciparum infection and 30 (0.3 %) a mixed infection. Of 
the 822 (8.4 %) patients with vivax infection 522 (63.5 %) 
did not meet the inclusion criteria, resulting in 300 
(57.5 %) patients enrolled. On cross checking of micros-
copy 12 (4 %) patients were later confirmed to have either 
a mixed species infection or no parasites and were, there-
fore, excluded from the study. A total of 288 patients 
were included in the analyses (Fig. 2): 89 in Shele, 52 in 
Guba, 57 in Batu and 90 in Shone.
More than half of the patients were male (56.3  %) 
and the median age was 8 years (IQR 4–18) with 70.8 % 
(204/288) patients aged less than 15 years old. There was 
marked heterogeneity between the study sites in regards 
to gender, age, body temperature, haemoglobin concen-
tration and parasite density at enrollment (Table 1).
The total median dose CQ administered was 27.9 mg/
kg body weight. Two patients received a total dosage 
below 20  mg/kg: one patient received 18.75  mg from 
three doses of medication and the other didn’t complete 
the entire treatment course before leaving the study (total 
of 10 mg). Overall 5.9 % (17/288) patients vomited their 
first dose of CQ and 0.3 % (1/288) their second dose.
Parasite clearance
In total, 49  % (141/288) of patients had cleared their 
peripheral parasitaemia when reviewed on day 1, 
88.2  % (254/288) by day 2 and 98.7  % (284/288) by day 
3. Whereas patients in Shele and Shone all cleared their 
parasites by day 3, 5.6  % (3/54) of the patients in Guba 
and 1.5  % (1/57) in Batu were still parasitaemic at this 
time (Fig. 3). Patients who were still parasitaemic at day 2 
had a significantly higher baseline parasitaemia (geomet-
ric mean 5284 µl−1 95 % CI 3525–7918) than those who 
were aparasitaemic (geometric mean 2446 µl−1 95 % CI 
2145–2788; p = 0.0003).
Efficacy outcomes
Of the 288 patients in the evaluable population 29 (10 %) 
patients were lost to follow up and 5 (1.7 %) had a P. fal-
ciparum parasitaemia during follow up. Early treatment 
failures (ETF) occurred in 2 (0.7 %) patients, both due to 
a slow clearance with patent parasitaemia on day 3 asso-
ciated with and an axillary temperature >37.5  °C. A late 
treatment failure (LTF) was observed in 23 (8 %) patients, 
eight of whom were classified as LCTF and 15 as LPTF. 
The overall risk of treatment failure at day 28 was 9.4 % 
(95 % CI 6.4–13.6 %) with site-specific estimates of 3.8 % 
(95 % CI 1.2–11.3) for Shele, 21.9 % (95 % CI 12.2–36.1) 
for Guba, 5.9  % (95  % CI 1.9–17.3) for Batu and 9.2  % 
(95  % CI 4.5–17.6) for Shone (Fig.  4). The median time 
to recurrence was 14 days (IQR 4–28), the time to recur-
rence being shorter in adults (median time 5.5 days, IQR 
4–7) compared to children (median time 14  days, IQR 
7–28).
Although the time to recurrence was not correlated 
significantly with baseline parasitaemia, patients failing 
treatment had a significantly higher baseline parasitaemia 
(geometric mean 5434  µl−1; 95  % CI 3238–9118) com-
pared to those successfully treated (2539  µl−1; 95  % CI 
2230–2890; p = 0.002). Patents with a baseline parasitae-
mia greater or equal than to 6234 µl−1 (the 75th percen-
tile), had an odds ratio (OR) for treatment failure of 3.75 
(95  % CI 1.62–8.65; p =  0.02). Patient failing the treat-
ment were also significantly younger than those success-
fully treated [mean age of 6.1 (SD 6.4) years compared to 
12.8 (SD 11.0) years; p = 0.003], and this remained sig-
nificant after controlling for baseline parasitaemia. There 
was no difference in the total dose per kilogram admin-
istered in patients who failed treatment and those who 
were treated successfully. There were a total of 18 (6.3 %) 
patients who vomited any dose of CQ. From those, only 
one (5.5 %) had a late treatment failure compared to 8.1 % 
(22/270) in those who did not vomit (p = 0.69).
Haemoglobin
The mean haemoglobin concentration at baseline was 
12.5  g/dL (95  % CI 12.3–12.78) and 12.5  g/dL (95  % CI 
12.3–12.8) at day 28, the risk of anaemia (Hb < 10 g/dL) 
being 18.5 % (51/175) and 16.4 % (35/214) at baseline and 
at day 28 respectively. Haemoglobin was significantly 
correlated with baseline parasite density (rho  =  −0.19, 
p =  0.0017), and also with age (rho =  0.11, p =  0.058). 
The risk of anaemia varied significantly between sites 
being greatest in Shele (49.4 %) (Table 1).
Discussion
The clinical efficacy study in four locations in southern 
Ethiopia show evidence of emerging CQ resistance in 
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the region, although there was marked heterogeneity in 
the risk of treatment failure between the study sites. The 
national treatment guidelines in Ethiopia recommend 
CQ for treatment of vivax malaria, although evidence of 
declining efficacy has raised significant concerns amongst 
local policy makers [9–11, 16–19]. In a recent study in 
Halaba, southern Ethiopia, 13.8 % (11/80) of patients had 
a recurrent P. vivax infection by day 28 [18], similar to 
the results in Shone which is approximately 30 km away.
Parasite recurrence can arise from either parasite resist-
ance to what should be a curative treatment regimen or inad-
equate treatment such as that from malabsorption, vomiting 
or poor drug quality, resulting in subcurative drug concen-
trations in the peripheral blood. Blood concentrations of 
Lost to FU 
n=14
Lost to FU 
n=2
Lost to FU 
n=5
Lost to FU 
n=8
ETF n=0
LTF n=3
ACPR n=69
ETF n=2 ETF n=0 ETF n=0
LTF n=9 LTF n=3 LTF n=8
ACPR n=39 ACPR n=47 ACPR n=74
P. falciparum
n=3
P. falciparum
n=2
Shele
n=89
Guba 
n=54
Batu 
n=57
Shone 
n=100
No parasites D0 
or mixed infect.
n=2
No parasites D0 
or mixed infect.
n=10
Included in analyses n=288
Total P. vivax n=822
No malaria n=8017
Mixed infecons n=30
P. falciparum n=868
Not meeng incl. criteria n=522
Total enrolled n=300
Total screened n=9737
Fig. 2 Flow chart of patients in the study
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CQ were not measured in this study, so it is not possible to 
rule out whether sub-therapeutic drug levels contributed to 
poor treatment outcome, which is a limitation of this study. 
However it is reassuring that all patients received a total 
dose of CQ greater than 27 mg/kg, suggesting that subopti-
mal dosing was unlikely to have been a contributing factor. 
Whilst poor absorption, particularly for the initial doses in 
febrile patients, may contribute to some treatment failure it 
is unlikely to have caused more than 5 % recurrences [7].
Recurrent P. vivax parasitaemia may be due to 
recrudescence of the same parasite, relapse from the 
reactivation of a dormant liver stage or a new infection. 
Relapses can occur as early as 21  days following initia-
tion of treatment. Recrudescent infections can occur late 
(up to 63 days); although the greater the degree of resist-
ance the earlier the recurrence is likely to occur. Whereas 
genotyping of polymorphic loci is undertaken rou-
tinely in P. falciparum drug efficacy trials to distinguish 
Table 1 Baseline data of the study population overall and per site
a Difference between sites
b Hb not recorded in 13 patients
Variable Shele Guba Batu Shone Overall p valuea
Total number of patients 89 52 57 90 288
Gender male (%) 58 (65.2 %) 30 (57.7 %) 23 (40.3 %) 51 (56.7 %) 162 (56.3 %) 0.032
Age
 Median age [IQR] in years 10 [4–18] 12 [4.5–22.5] 12 [6–20] 6 [4–9] 8 [4–18] 0.0022
  ≤5 year 31 (34.8 %) 16 (30.8 %) 13 (22.8 %) 43 (47.8 %) 103 (35.8 %)
  5 to ≤15 years 26 (29.2 %) 18 (34.6 %) 24 (42.1 %) 33 (36.7 %) 101 (35.1 %)
  >15 years 32 (35.9 %) 18 (34.6 %) 20 (35.1 %) 14 (15.6 %) 84 (29.2 %)
Body weight
 Median weight [IQR] in kg 22.5 [14–50] 26.5 [15–44] 35 [16.3–50.1] 20 [17–26] 22 [16–45] 0.24
 Median mg/kg [IQR] total dose of 
chloroquine
27.3 [25–30] 27.0 [25–30] 26.7 [23.6–28.8] 31.25 [26.98–37.5] 27.9 [25–30.8] 0.0001
Enrolment clinical parameters
 Mean (SD) temperature °C 37.5 (0.82) 37.6 (1.18) 37.0 (0.74) 37.0 (0.68) 37.3 (0.88) 0.0003
 Fever (temp >37.5 °C) N (%) 44 (49.4 %) 20 (38.5 %) 18 (31.6 %) 25 (27.8 %) 107 (37.2 %) 0.019
 Geometric mean parasitaemia µl−1  
[95 % CI]
3112 [1483–3899] 6527 [4709–9046] 1961 [1661–2314] 1751 [1417–2164] 2712 [2387–3082] 0.0001
 Gametocyte carriage N (%) 86 (96.7 %) 22 (42.3 %) 5 (8.8 %) 61 (67.8 %) 174 (60.4 %) 0.000
 Geometric mean gametocyte density 
µl−1 [95 % CI]
334 [257–435] 99 [66–148.5] 146 [60–355.1] 26 [20.2–34] 114 [90.3–145.8] 0.000
 Mean haemoglobin (SD)b 10.6 (1.9) 12.1 (1.5) 13.8 (1.7) 14.0 (1.3) 12.5 (2.2) 0.0001
 Anaemic (Hb < 10 g/dL) N (%)b 44 (49.4 %) 5 (9.8 %) 2 (3.6 %) 0 51 (18.5 %) 0.000
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new infections from true parasite recrudescence [20], 
in P. vivax the interpretation of molecular typing is less 
informative. Heterologous paired isolates from pre- and 
post-treatment help to rule out true recrudescence, 
however homologous infection can be due to either 
recrudescence or relapse [21–23]. Importantly since CQ 
has a long terminal elimination, any parasite recurring 
within 28  days is likely to have done so in the presence 
of high drug concentrations expected to be above the 
minimum inhibitory concentration of CQ sensitive iso-
lates (100 nM). As such the day of recurrence is as useful 
measure of CQ resistance (CQR) in the population.
There was noted heterogeneity in the risk of recurrence 
between and within sites. Treatment failure was higher in 
patients who were younger, and had a higher parasitaemia 
at enrollment. Both of these factors are well recognized 
as important risk factors for failure in P. falciparum clini-
cal trials [24, 25]. High baseline parasitaemia is associ-
ated with prolonged parasite clearance, which is a reliable 
predictor of parasite recrudescence. Previous studies in P. 
vivax have demonstrated a similar relationship [26] sug-
gesting that rapid clearance (95 % by day 2 or 100 % by day 
3) may be a useful marker of CQ sensitivity [7]. In the cur-
rent study, two sites fulfilled these criteria and although 
CQ efficacy in Shele was adequate (>96.2  %), in Shone 
there was evidence of emerging CQR (efficacy of 90.8 % 
95 % CI 82.4–95.3). The population enrolled in Guba had 
the lowest efficacy with 21.9 % risk of recurrence, and this 
site also recorded more than 20 % parasitaemia on day 2 
and more than 5 % on day 3 (Fig. 3). This site had also a 
significantly higher enrollment parasite density compared 
to the other three sites. The risk of recurrence in Guba 
suggests significant degree of CQR, however efficacy is 
likely to have been further compromised by the high lev-
els of parasitaemia at presentation [27].
Conclusions
Overall this study highlights evidence of clinical treat-
ment failure after CQ most likely due to CQ resistance 
emerging in three out of four sites in southern Ethiopia. 
The data supports calls for increased drug resistance 
monitoring and re-evaluation of treatment guidelines.
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